Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study

Authors

  • Marcello Dallio Department of Clinical and Experimental Medicine, L. Vanvitelli University of Campania, Naples, Italy
  • Mario Masarone Department of Medicine and Surgery, University of Salerno, Baronissi, Salerno, Italy
  • Giuseppe Gerardo Caprio Department of Clinical and Experimental Medicine, L. Vanvitelli University of Campania, Naples, Italy
  • Rosa Di Sarno Department of Clinical and Experimental Medicine, L. Vanvitelli University of Campania, Naples, Italy
  • Concetta Tuccillo Department of Clinical and Experimental Medicine, L. Vanvitelli University of Campania, Naples, Italy
  • Ferdinando Carlo Sasso Department of Clinical and Experimental Medicine, L. Vanvitelli University of Campania, Naples, Italy
  • Marcello Persico Department of Medicine and Surgery, University of Salerno, Baronissi, Salerno, Italy
  • Carmela Loguercio Department of Clinical and Experimental Medicine, L. Vanvitelli University of Campania, Naples, Italy
  • Alessandro Federico Department of Clinical and Experimental Medicine, L. Vanvitelli University of Campania, Naples, Italy

DOI:

https://doi.org/10.15403/jgld.2014.1121.263.dal

Keywords:

Endocan, Non Alcoholic Fatty Liver Disease, Type 2 diabetes mellitus

Abstract

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is emerging as an independent cardiovascular risk factor. Recently, Endocan has been studied as an early marker of endothelial dysfunction. Our aim was to evaluate Endocan serum levels in patients with NAFLD with or without type 2 diabetes mellitus.
Method: We enrolled 56 patients: 19 with NAFLD and 37 with type 2 diabetes mellitus with or without NAFLD, and compared them to 25 healthy controls. Endocan serum level was measured by using the ELISA EndoMark assay.
Results: Endocan level was significantly higher in NAFLD subjects, compared to controls (1.23±1.51 vs 0.68±0.4 ng/mL; p=0.016). It was higher in patients with non-alcoholic fatty liver and non-alcoholic steatohepatitis (NASH) (1.12±1.11, 1.49±2.16 and 0.68±0.4 ng/ml vs controls, respectively), independently from presence of type 2 diabetes mellitus. The increase was more marked in patients with NASH and in those with NAFL versus controls (p=0.001 and p=0.004, respectively), but not statistically different between the two groups (p=0.448). Finally, we found a statistically relevant increase of this marker in diabetic NAFLD patients compared to those non diabetic (1.56±0.81 vs 0.72±0.58 ng/ml; p=0.01).
Conclusion: We demonstrated an increased Endocan serum level in NAFLD patients, higher in those with type 2 diabetes mellitus and/or NASH because of an endothelial dysfunction in these pathologies.
Abbreviations: BMI: Body Mass Index; CCBS: calcium channel blockers; ED: endothelial dysfunction; ELISA: enzyme-linked immunosorbent assay; ESM-1: Endothelial cell-specific molecule-1; HOMA-IR: Homeostasis Model Assessment Insulin Resistance; ICAM: Intercellular Adhesion Molecule; LFA-1: Lymphocyte Function-Associated Antigen 1; NAFL: non-alcoholic fatty liver; NAFLD: Non-alcoholic fatty liver disease; NAS: non-alcoholic fatty liver disease activity score; NASH: non-alcoholic steatohepatitis; ROS: reactive oxigen species; T2DM: type 2 diabetes mellitus; TNF-alpha: tumor necrosis factor-alpha.

Downloads

Published

2017-09-01

How to Cite

1.
Dallio M, Masarone M, Caprio GG, Di Sarno R, Tuccillo C, Sasso FC, Persico M, Loguercio C, Federico A. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. JGLD [Internet]. 2017 Sep. 1 [cited 2026 Aug. 11];26(3):261-8. Available from: https://jgld.ro/jgld/index.php/jgld/article/view/981

Issue

Section

Original Article